11 recruiting, 11 unknown, 10 completed, 7 terminated. 24 Phase 2, 20 Phase 3, 4 Not applicable, 1 Phase 1.
Follow Induction Chemotherapy: new trials by email Literature Review of Induction Chemotherapy trials Research Report on Induction Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Dinutuximab Beta, Induction chemotherapy - High Risk Neuroblastoma | Phase 1 | Recruiting | Chang Gung Memorial Hospital | 30 | 2026-07-01 | 2026-10-06 |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Recruiting | J. W. A. Burger | 394 | 2026-03-16 | 2026-10-27 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma Immunotherapy, Induction chemotherapy, D2 radical gastrectomy - Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 15 | 2026-01-31 | 2026-01-07 |
| Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy) - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Second Affiliated Hospital of Zunyi Medical University | 92 | 2026-01-01 | 2026-04-30 |
| IMPT Dose Escalation for NSCLC (HyDose) Dose-escalated intensity-modulated proton therapy (IMPT-74), Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy, Immunotherapy: adjuvant durvalumab - Carcinoma, Non-Small-Cell Lung | Not applicable | Recruiting | University Medical Center Groningen | 87 | 2025-09-01 | 2026-01-30 |
| PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation - Esophageal Cancer, Oesophageal Cancer | Phase 2 | Recruiting | Medical College of Wisconsin | 50 | 2025-06-17 | 2026-07-28 |
| Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia Blinatumomab, Induction Chemotherapy, Hyper-CVAD - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 101 | 2025-04-01 | 2026-05-04 |
| Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC Intensity-modulated proton radiation therapy, Intensity-modulated photon radiation therapy, Intensity-modulated carbon ion radiation therapy - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Lin Kong, MD | 470 | 2025-04-01 | 2025-12-02 |
| Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA induction chemotherapy (mDCF), Concomitant chemotherapy (Capecitabin + Mitomycin-C), radiotherapy - Anal Cancer | Phase 3 | Recruiting | Federation Francophone de Cancerologie Digestive | 310 | 2024-02-26 | 2025-09-02 |
| IC Plus Low-dose Radiation Plus Cadonilimab in LANPC Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor | Phase 3 | Recruiting | Sun Yat-sen University | 380 | 2024-01-10 | 2026-05-11 |
| Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy) - Nasopharyngeal Carcinoma | Phase 3 | Active not recruiting | Sun Yat-sen University | 464 | 2023-09-07 | 2026-08-12 |
| A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy Induction chemotherapy plus Concurrent chemotherapy, Concurrent chemotherapy, IMRT - Nasopharyngeal Carcinoma | Not applicable | Not yet recruiting | Sun Yat-sen University | 236 | 2022-11-30 | 2022-11-18 |
| Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT Toripalimab, Induction chemotherapy and concurrent chemoradiation - Nasopharyngeal Cancer | Phase 2 | Recruiting | Fudan University | 198 | 2022-07-02 | 2022-11-29 |
| Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain IMRT, induction chemotherapy, cisplatin concurrent chemotherapy - Nasopharyngeal Carcinoma | Phase 3 | Active not recruiting | Sun Yat-sen University | 452 | 2022-05-11 | 2025-03-21 |
| Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer induction chemotherapy and immunotherapy - ESCC | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 44 | 2022-01-01 | 2025-06-11 |
| ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma Induction Chemotherapy, Concurrent Chemotherapy, Definitive Radiotherapy - Locally Advanced Nasopharyngeal Carcinoma | Phase 3 | Recruiting | First Affiliated Hospital, Sun Yat-Sen University | 447 | 2021-09-22 | 2021-09-30 |
| Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma Induction chemotherapy, Carbon-ion radiotherapy, Camrelizumab - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Shanghai Proton and Heavy Ion Center | 146 | 2021-01-19 | 2022-04-29 |
| Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma Anlotinib hydrochloride, induction chemotherapy, concurrent chemoradiation - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Zhejiang Cancer Hospital | 37 | 2021-01-01 | 2022-02-10 |
Showing 20 of 48. Sign in to see all of them.
Nasopharyngeal Carcinoma (11) · Leukemia, Myeloid, Acute (6) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (3) · Nasopharyngeal Neoplasms (3) · Myelodysplastic Syndromes (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma (1) · Anemia, Refractory, with Excess of Blasts (1) · Anus Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Squamous Cell (1) · Central Nervous System Neoplasms (1)
Sun Yat-sen University (7) · First Affiliated Hospital of Zhejiang University (2) · AHEPA University Hospital (1) · Barretos Cancer Hospital (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Chang Gung Memorial Hospital (1) · Chaosu Hu (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Eisai Inc. (1) · Federation Francophone de Cancerologie Digestive (1) · Feng Jing (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · First People's Hospital of Foshan (1) · Fudan University (1) · Genmab (1)
China (20) · France (8) · United States (8) · Netherlands (4) · Brazil (3) · Spain (3) · United Kingdom (3) · Belgium (2) · Germany (2) · India (2) · Italy (2) · Australia (1) · Austria (1) · Czechia (1) · Denmark (1)
A. Van der Wekken, MD PhD (1) · Amar Gajjar, MD (1) · Brian Shaffer, MD (1) · Chao-su Hu, M.D. (1) · Chong Zhao, MD, PhD (1) · Chunmei Bai (1) · E. Korevaar, dr ir (PhD) (1) · Fabio P Santos, MD (1) · Fan Zhimin, Professor (1) · Fang-Yun Xie, M.D (1) · Francois Doz, Prof. Dr. (1)
PMID 15625363, PMID 16079161, PMID 16606972, PMID 17579184, PMID 18502088, PMID 19505212, PMID 19732686, PMID 19906561, PMID 22261362, PMID 23077109, PMID 27567280, PMID 28129526, PMID 28688693, PMID 29778738, PMID 30106636, PMID 31150573, PMID 31640628, PMID 32898792, PMID 33502920, PMID 33945291, PMID 35183221, PMID 35709465, PMID 37280275, PMID 38205914, PMID 40705321, PMID 40802908, PMID 40967259, PMID 42151882, PMID 9215816
2009 (1), 2025 (1), R01CA154619 (1), U10CA032102 (1)